



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2012

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 12/31/2012 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 12/31/2011 RM'000	CURRENT YEAR TO DATE 12/31/2012 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 12/31/2011 RM'000
Revenue	35,378	33,036	135,310	138,132
Cost of Sales	(18,471)	(15,817)	(72,361)	(74,847)
Gross Profit	16,907	17,219	62,949	63,285
Other operating income	763	69	1,356	247
Distribution costs	(2,053)	(4,189)	(11,295)	(12,415)
Administration expenses	(3,343)	(3,437)	(12,327)	(12,871)
Other operating expenses	(3,223)	(1,730)	(5,085)	(3,612)
Profit from operations	9,051	7,932	35,598	34,634
Finance income	12	42	101	365
Finance costs	(63)	(138)	(401)	(271)
Profit before taxation	9,000	7,836	35,298	34,728
Taxation	(3,002)	(1,507)	(9,283)	(8,023)
Profit after tax for the period	5,998	6,329	26,015	26,705
Other comprehensive income	-	-	-	-
Total other comprehensive income for the period	5,998	6,329	26,015	26,705
Profit attributable to:				
Shareholders of the Company	5,998	6,329	26,015	26,705
Minority interest	-	-	-	-
	5,998	6,329	26,015	26,705
Total other comprehensive income attributable to:				
Shareholders of the Company	5,998	6,329	26,015	26,705
Minority interest	-	-	-	-
	5,998	6,329	26,015	26,705
Earnings per share (sen)				
Basic (based on weighted average)	4.32	4.56	18.74	19.24
Diluted (based on weighted average)	4.32	4.56	18.74	19.24

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2012

	AS AT 31/12/2012 RM'000	AS AT 31/12/2011 RM'000 Restated (*)	AS AT 1/1/2011 RM'000 Restated (*)
ASSETS			
Property, Plant and Equipment	98,940	95,977	100,249
Investment properties	6,470	5,720	-
Total non-current assets	<u>105,410</u>	<u>101,697</u>	<u>100,249</u>
Inventories	41,383	45,124	34,003
Trade & Other Receivables	35,481	36,911	34,804
Amount Due From Related Company	1,617	769	951
Current tax assets	-	2,695	-
Assets classified as held for sale	-	1,740	1,740
Cash & Cash Equivalents	14,139	8,584	24,732
Total current assets	<u>92,620</u>	<u>95,823</u>	<u>96,230</u>
Total Assets	<u><u>198,030</u></u>	<u><u>197,520</u></u>	<u><u>196,479</u></u>
EQUITY			
Share Capital	69,739	69,739	69,739
Reserves	13,720	13,720	13,720
Retained earnings	88,623	82,564	75,988
Treasury Shares	(1,578)	(1,578)	(1,578)
Total Equity	<u>170,504</u>	<u>164,445</u>	<u>157,869</u>
LIABILITIES			
Deferred Tax Liability	5,659	5,584	3,821
Borrowings	-	2,082	10,416
Total non-current liabilities	<u>5,659</u>	<u>7,666</u>	<u>14,237</u>
Trade & Other Payables	15,657	14,304	13,509
Amount due to related company	823	2,005	1,324
Provision	341	766	850
Taxation	46	-	356
Borrowings	5,000	8,334	8,334
Total current liabilities	<u>21,867</u>	<u>25,409</u>	<u>24,373</u>
Total Liabilities	<u><u>27,526</u></u>	<u><u>33,075</u></u>	<u><u>38,610</u></u>
Total Equity & Liabilities	<u><u>198,030</u></u>	<u><u>197,520</u></u>	<u><u>196,479</u></u>
Net assets per share (RM)	1.22	1.18	1.13

* Upon adoption of MFRS, the Condensed Consolidated Statement of Financial Positions at 31 December 2011 and 1 January 2011 have been restated accordingly.

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2012

	31 December 2012	31 December 2011
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	35,298	34,728
Adjustments for:		
Depreciation of property, plant and equipment	6,974	5,969
Provision for product warranty	(425)	
Interest income	(101)	(365)
Finance costs	403	271
Change in fair value for Investment Property	(750)	-
Gain on disposal of property, plant and equipment	(600)	-
<i>Operating profit before changes in working capital</i>	<u>40,799</u>	<u>40,603</u>
(Increase)/decrease in inventories	3,741	(11,122)
(Increases)/decrease in receivables, deposits and prepayments	162	(1,959)
Increase/(decrease) in payables and accruals	591	1,427
<i>Cash generated from operations</i>	<u>45,293</u>	<u>28,949</u>
Finance costs paid	(403)	(271)
Interest income	101	365
Income tax paid	(6,467)	(9,311)
Net cash generated from operating activities	<u>38,524</u>	<u>19,732</u>
Cash flows from investing activities		
Acquisition of property, plant and equipment	(9,938)	(7,417)
Proceed from disposal of property, plant and equipment	2,341	-
Net cash used in investing activities	<u>(7,597)</u>	<u>(7,417)</u>
Cash flows from financing activities		
Drawdown of borrowings	5,000	-
Repayment of borrowings	(10,416)	(8,334)
Dividends paid to shareholders of the Company	(19,956)	(20,129)
Net cash used in financing activities	<u>(25,372)</u>	<u>(28,463)</u>
Net increase/(decrease) in cash and cash equivalents	5,555	(16,148)
Cash and cash equivalents at 1 January	8,584	24,732
Cash and cash equivalents as at 30 Dec	<u>14,139</u>	<u>8,584</u>
 (l) Cash and cash equivalents comprise:		
	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	9,346	568
Fixed deposits placed with licensed financial institutions	4,793	8,016
	<u>14,139</u>	<u>8,584</u>

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2011 and the accompanying explanatory notes attached to the interim financial statements.)